Introduction: Technological advancements have been such that today the indwelling vocal prostheses, in laryngectomyzed patients, are designed to meet the criteria of low airflow resistance, optimal retention in the tracheoesophageal party wall, prolonged device lifetime, simple maintenance by patient and comfortable outpatient replacement. The aim of this study was to assess the initial clinical experience using third generation of vocal prosthesis (Provox Vega). Materials and method: A retrospective study was carried out with 54 laryngectomized patients during the period 2011-2015. Patients were rehabilitated with indwelling Provox Vega 17 and 20 Fr. Fourteen patients were considered normal patients (Group A); thirteen patients received postoperative radiotherapy (Group B); sixteen patients were categorized as GERD patients (Group C) and eleven subject as elderly patients (Group D). Results: The mean in situ Vega lifetime was 193 days (range: 144-243) in group A, 168 days: (range 125-182) in group B, 123 days (range: 97-134) in group C and 240 days in group D (range: 205-328). Overall, the prosthetic lifetime average was 187.5 days. The Harrison-Robillard-Schultz score, did not show statistically significant differences with the reference groups. Conclusion: The study in question showed an overall better results in terms of lifetime and use, quality and care of the rehabilitation level, but nonetheless comparable with those present in the literature and previously registered, in terms of statistical significance.

Clinical experience with third generation of vocal prosthesis in laryngectomized patients

COCUZZA, SALVATORE GIUSEPPE;MAIOLINO, Luigi;DI MAURO P.
2016

Abstract

Introduction: Technological advancements have been such that today the indwelling vocal prostheses, in laryngectomyzed patients, are designed to meet the criteria of low airflow resistance, optimal retention in the tracheoesophageal party wall, prolonged device lifetime, simple maintenance by patient and comfortable outpatient replacement. The aim of this study was to assess the initial clinical experience using third generation of vocal prosthesis (Provox Vega). Materials and method: A retrospective study was carried out with 54 laryngectomized patients during the period 2011-2015. Patients were rehabilitated with indwelling Provox Vega 17 and 20 Fr. Fourteen patients were considered normal patients (Group A); thirteen patients received postoperative radiotherapy (Group B); sixteen patients were categorized as GERD patients (Group C) and eleven subject as elderly patients (Group D). Results: The mean in situ Vega lifetime was 193 days (range: 144-243) in group A, 168 days: (range 125-182) in group B, 123 days (range: 97-134) in group C and 240 days in group D (range: 205-328). Overall, the prosthetic lifetime average was 187.5 days. The Harrison-Robillard-Schultz score, did not show statistically significant differences with the reference groups. Conclusion: The study in question showed an overall better results in terms of lifetime and use, quality and care of the rehabilitation level, but nonetheless comparable with those present in the literature and previously registered, in terms of statistical significance.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/20.500.11769/20290
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact